ABT · Abbott Laboratories
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-30 | Gonzalez Patricia Paola |
Director |
Award↑
Filing footnotes — Stock Equivalent Units (Direct)
Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. |
Stock Equivalent Units
|
363 |
| 2026-06-30 | Roman Michael F |
Director |
Award↑
Filing footnotes — Stock Equivalent Units (Direct)
Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. |
Stock Equivalent Units
|
416 |
| 2026-06-30 | Ahuja Nita |
Director |
Award↑
Filing footnotes — Stock Equivalent Units (Direct)
Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. |
Stock Equivalent Units
|
347 |
| 2026-06-30 | Conroy Kevin T |
Director |
Award↑
Filing footnotes — Stock Equivalent Units (Direct)
Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. |
Stock Equivalent Units
|
231 |
| 2026-06-30 | Stratton John G |
Director |
Award↑
Filing footnotes — Stock Equivalent Units (Direct)
Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. |
Stock Equivalent Units
|
432 |
| 2026-06-30 | Morrone Louis H. |
EXECUTIVE VICE PRESIDENT |
Tax↓
|
Common shares without par value
|
269 |
| 2026-06-27 | Cushman Elizabeth C. |
EVP, GC AND SECRETARY |
Tax↓
|
Common shares without par value
|
560 |
| 2026-05-07 | Stratton John G |
Director |
Buy↑
|
Common shares without par value
|
2,000 |
| 2026-04-28 | Moreland Mary K |
EXECUTIVE VICE PRESIDENT |
Discretionary↑
Filing footnotes — Common shares without par value (Indirect)
Balance in the Abbott Laboratories Stock Retirement Trust as of April 28, 2026. |
Common shares without par value
(I)
|
5,314 |
| 2026-04-27 | STARKS DANIEL J |
Director |
Buy↑
Filing footnotes — Common shares without par value (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.43 to $93.04, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common shares without par value
|
10,000 |
| 2026-04-24 | McKinstry Nancy |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3. |
Option (right to buy)
|
2,305 |
| 2026-04-24 | Stratton John G |
Director |
Award↑
Filing footnotes — Common shares without par value (Direct)
Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
Common shares without par value
|
2,286 |
| 2026-04-24 | STARKS DANIEL J |
Director |
Award↑
Filing footnotes — Common shares without par value (Direct)
Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
Common shares without par value
|
2,286 |
| 2026-04-24 | Roman Michael F |
Director |
Award↑
Filing footnotes — Common shares without par value (Direct)
Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
Common shares without par value
|
2,286 |
| 2026-04-24 | McDew Darren W |
Director |
Award↑
Filing footnotes — Common shares without par value (Direct)
Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
Common shares without par value
|
2,286 |
| 2026-04-24 | Kumbier Michelle |
Director |
Award↑
Filing footnotes — Common shares without par value (Direct)
Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
Common shares without par value
|
2,286 |
| 2026-04-24 | O'Grady Michael |
Director, Chairman and CEO |
Award↑
Filing footnotes — Common shares without par value (Direct)
Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
Common shares without par value
|
2,286 |
| 2026-04-24 | Blount Sally E. |
Director |
Award↑
Filing footnotes — Common shares without par value (Direct)
Restricted stock unit award granted under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
Common shares without par value
|
2,286 |
| 2026-04-24 | Gonzalez Patricia Paola |
Director |
Award↑
Filing footnotes — Common shares without par value (Direct)
Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
Common shares without par value
|
2,286 |
| 2026-04-24 | McKinstry Nancy |
Director |
Award↑
Filing footnotes — Common shares without par value (Direct)
Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
Common shares without par value
|
2,286 |
| 2026-04-24 | Conroy Kevin T |
Director |
Award↑
Filing footnotes — Common shares without par value (Direct)
Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined by the Program). |
Common shares without par value
|
2,286 |
| 2026-04-24 | STARKS DANIEL J |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3. |
Option (right to buy)
|
7,105 |
| 2026-04-24 | Babineaux-Fontenot Claire |
Director |
Award↑
Filing footnotes — Common shares without par value (Direct)
Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
Common shares without par value
|
2,286 |
| 2026-04-24 | O'Grady Michael |
Director, Chairman and CEO |
Award↑
Filing footnotes — Option (right to buy) (Direct)
Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3. |
Option (right to buy)
|
5,929 |
| 2026-04-24 | Ahuja Nita |
Director |
Award↑
Filing footnotes — Common shares without par value (Direct)
Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
Common shares without par value
|
2,286 |
| 2026-04-23 | Boudreau Philip P |
EVP AND CFO |
Buy↑
|
Common shares without par value
(I)
|
2,200 |
| 2026-04-23 | Boudreau Philip P |
EVP AND CFO |
Discretionary↑
Filing footnotes — Common shares without par value (Indirect)
Balance in the Abbott Laboratories Stock Retirement Trust as of April 23, 2026. |
Common shares without par value
(I)
|
8,909 |
| 2026-03-31 | Gonzalez Patricia Paola |
Director |
Award↑
Filing footnotes — Stock Equivalent Units (Direct)
Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. |
Stock Equivalent Units
|
321 |
| 2026-03-31 | Alpern Robert J |
Director |
Award↑
Filing footnotes — Stock Equivalent Units (Direct)
Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. |
Stock Equivalent Units
|
76 |
| 2026-03-31 | Roman Michael F |
Director |
Award↑
Filing footnotes — Stock Equivalent Units (Direct)
Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. |
Stock Equivalent Units
|
367 |
| 2026-03-31 | Ahuja Nita |
Director |
Award↑
Filing footnotes — Stock Equivalent Units (Direct)
Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. |
Stock Equivalent Units
|
102 |
| 2026-03-31 | Stratton John G |
Director |
Award↑
Filing footnotes — Stock Equivalent Units (Direct)
Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. |
Stock Equivalent Units
|
382 |
| 2026-03-23 | ORVILLE JACOB A |
EVP, GM, Screening |
Award↑
Filing footnotes — Common shares without par value (Direct)
These shares represent a restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 2-year term, with 1/2 of the award vesting in any one year, beginning on March 23, 2027. The award includes the right to have shares withheld for tax purposes. |
Common shares without par value
|
13,255 |
| 2026-03-02 | Shroff Eric |
Senior Vice President |
Sell↓
|
Common shares without par value
|
709 |
| 2026-03-02 | Salvadori Daniel Gesua Sive |
EVP AND GROUP PRESIDENT |
Sell↓
|
Common shares without par value
|
885 |
| 2026-03-02 | Morrone Louis H. |
EXECUTIVE VICE PRESIDENT |
Sell↓
|
Common shares without par value
|
1,144 |
| 2026-03-02 | Cushman Elizabeth C. |
EVP, GC AND SECRETARY |
Sell↓
|
Common shares without par value
|
263 |
| 2026-03-02 | MCCOY JOHN A. JR. |
VICE PRESIDENT AND CONTROLLER |
Sell↓
|
Common shares without par value
|
585 |
| 2026-03-02 | Moreland Mary K |
EXECUTIVE VICE PRESIDENT |
Sell↓
|
Common shares without par value
|
613 |
| 2026-02-27 | Earnhardt Lisa D |
EVP AND GROUP PRESIDENT |
Tax↓
|
Common shares without par value
|
8,577 |
| 2026-02-27 | Shroff Eric |
Senior Vice President |
Tax↓
|
Common shares without par value
|
1,384 |
| 2026-02-27 | Cushman Elizabeth C. |
EVP, GC AND SECRETARY |
Tax↓
|
Common shares without par value
|
1,421 |
| 2026-02-27 | Salvadori Daniel Gesua Sive |
EVP AND GROUP PRESIDENT |
Tax↓
|
Common shares without par value
|
6,615 |
| 2026-02-27 | Moreland Mary K |
EXECUTIVE VICE PRESIDENT |
Tax↓
|
Common shares without par value
|
4,630 |
| 2026-02-27 | Boudreau Philip P |
EVP AND CFO |
Tax↓
|
Common shares without par value
|
7,441 |
| 2026-02-27 | Morrone Louis H. |
EXECUTIVE VICE PRESIDENT |
Tax↓
|
Common shares without par value
|
4,040 |
| 2026-02-27 | Scoggins Christopher J |
EXECUTIVE VICE PRESIDENT |
Tax↓
|
Common shares without par value
|
4,997 |
| 2026-02-27 | Ford Robert B |
Director, CHAIRMAN AND CEO |
Tax↓
|
Common shares without par value
|
30,308 |
| 2026-02-27 | MCCOY JOHN A. JR. |
VICE PRESIDENT AND CONTROLLER |
Tax↓
|
Common shares without par value
|
1,142 |
| 2026-02-24 | Shroff Eric |
Senior Vice President |
Award↑
Filing footnotes — Option (right to buy) (Direct)
Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,940 on February 24, 2027, 14,940 on February 24, 2028, and 14,941 on February 24, 2029. |
Option (right to buy)
|
44,821 |